---
schema_version: "secwatch.filing_event.v1"
accession: "0001299130-23-000093"
form_type: "8-K"
ticker: "PACB"
cik: "0001299130"
company_name: "PACIFIC BIOSCIENCES OF CALIFORNIA, INC."
filed_at: "2023-08-02T23:59:59+00:00"
generated_at: "2026-06-12T12:03:35.562181+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# PacBio Q2 revenue $47.6M (+34% YoY); acquires Apton for up to $110M; Onso shipments start

## Summary
- Q2 revenue $47.6M (+34% YoY); Revio drove record revenue with 45 systems shipped.
- Net loss $69.8M ($0.28 GAAP EPS); non-GAAP net loss $65.6M ($0.26).
- Acquired Apton Biosystems for ~$85M in stock plus up to $25M contingent milestone, valued up to ~$110M.
- Commercial shipments of Onso short-read sequencer commenced; first customer shipment today.
- Cash and investments $829.9M at June 30; issued $441M 1.375% convertible notes due 2030.

## SEC filing metadata
- accession: 0001299130-23-000093
- form_type: 8-K
- ticker: PACB
- cik: 0001299130
- company_name: PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
- filed_at: 2023-08-02T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1299130/000129913023000093/0001299130-23-000093-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1299130/000129913023000093/pacb-20230802.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001299130-23-000093
- JSON: https://secwatch.observer/filing/0001299130-23-000093.json
- Plain text: https://secwatch.observer/filing/0001299130-23-000093.txt

## Key facts
- Earnings Releases
  PACIFIC BIOSCIENCES OF CALIFORNIA, INC. reported the quarter ended June 30, 2023 results: revenue $47.6 million, net income $69.8 million, EPS $0.28.
  - Period: the quarter ended June 30, 2023
  - Revenue: $47.6 million
  - Net income: $69.8 million
  - EPS: $0.28
  - Result: reported results
  source text: Revenue of $47.6 million, a 34% increase compared with $35.5 million in the prior-year period. • Recognized revenue on 47 sequencing systems in the second quarter, including 45 Revio systems and 2 Sequel IIe systems, compared to 36 Sequel II/IIe systems in the prior-year period. • Instrument revenue of $29.9 million compared with $15.6 million in the prior-year period. • Consumables revenue of $13.7 million compared with $14.6 million in the prior-year period. • Service and other revenue of $3.9 million compared with $5.3 million in the prior-year period. Gross profit for the second quarter of 2023 was $15.5 million, representing a 4% decrease compared with $16.2 million for the second quarter of 2022 and a gross margin of 33% in the second quarter of 2023 compared to 46% for the second quarter of 2022. Non-GAAP gross profit for the second quarter of 2023 was $15.7 million and represented a non-GAAP gross margin of 33% in the second quarter of 2023, compared to a non-GAAP gross profit
  evidence_url: https://www.sec.gov/Archives/edgar/data/1299130/000129913023000093/0001299130-23-000093-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.